Cell Cycle Kinetics in Vivo in Patients With Hematologic Malignancies Studied by Iododeoxyuridine and Bromodeoxyuridine Labelling
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Hematologic Malignancies
Both
Hematologic Malignancies
Trial Information
Cell Cycle Kinetics in Vivo in Patients With Hematologic Malignancies Studied by Iododeoxyuridine and Bromodeoxyuridine Labelling
Cell cycle parameters include LI, Ts, Tc, T dpot, changes in these parameters, and
differences between normal and leukemic cells in patients with hematologic malignancy prior
to and following treatment.
Inclusion Criteria
Histologic proof of one of:
- AML, ALL, or AUL
- MDS or CMML
- CML
- OR undergoing bone marrow transplantation.
Participants should be:
- off therapy for at least two weeks
- At least 18 years old or older
- Using adequate contraception if of child-bearing capability.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Principal Investigator
Michael Andreeff, MD, PhD
Investigator Role:
Study Chair
Investigator Affiliation:
M.D. Anderson Cancer Center
Authority:
United States: Food and Drug Administration
Study ID:
DM91-102
NCT ID:
NCT00042250
Start Date:
May 1992
Completion Date:
October 2002
Related Keywords:
- Hematologic Malignancies
- Cell Cycle Interphase
- G0
- G1
- G2
- S Phase
- Neoplasms
- Hematologic Neoplasms
Name | Location |
|---|---|
| M.D. Anderson Cancer Center | Houston, Texas 77030 |
